The united states. I am guy johnson. I am Francine Lacqua and this is the pulse. It has been a bit of a day when it comes to m a. It is a merger monday. Pfizer has confirmed a possible offer for astrazeneca. Thats talk about what is happening in the pharmaceutical sector. Here with me is manus cranny and sam. Gentlemen, good morning. It has been a busy morning. We have bayer to talk about as well. Lets Start Talking about this astro transaction. Maybe this isnt such a great deal but is being driven more by pfizer wanting to put all that cash it has got sitting overseas to work rather than any rational use of that money. As you rightly say, there is quite a few variety of ideas coming out here. At the end of the day, when they broke the rumor last week, everyone was going, maybe it doesnt come and beat me it does make sense. Hadreality is that pfizer approached once, approach twice. Convinced that they can sell to their shareholders and astrazeneca shareholders. Things we dont know abou
The central part of the last election, and you want to deny the fact that elections make a difference. And so with that after a latenight session in the house, lawmakers voted to pass a bill that would keep the government funded past tomorrow, but House Republicans attached a oneyear delay to the Affordable Care act and repeal of a tax on those medical devices that help to fund the health care law. It is a measure that the Senate Democratic leader harry reid says he wont consider. Something the white house said the president will veto. With all of that, the federal for ament is headed possible shutdown. The house returns tomorrow morning at 10 00 eastern time. The senate is back tomorrow afternoon and as the deadline looms, any agreement needs to be in place before midnight of thee portions government will be game to close their doors. We welcome your calls. You can also join us on social media. Send us a tweet or on facebook at facebook outcome cspan. Our email address is journal at c
Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.